Skip to main content
SpringerLink
Log in

Parkinson-Syndrom

  • Chapter
Book cover Medikamentös induzierte neurologische und psychiatrische Störungen

  • 801 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 19.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 37.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Alvarez-Gomez MJ, Vaamonde J, Narbona J et al. (1993) Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol 16: 451–455

    Article  PubMed  CAS  Google Scholar 

  • Armon C, Shin C, Miller P, Carwile S, Brown E, Edinger JD, Paul RG (1996) Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 47: 626–635

    PubMed  CAS  Google Scholar 

  • Ayd F (1961) A survey of drug-induced extrapyramidal reactions. JAMA 175: 1054–1060

    PubMed  CAS  Google Scholar 

  • Balmaceda CM, Walker RW, Castro-Malaspina H, Dalmau J (1994) Reversal of amphotericin-B-related encephalopathy. Neurology 44: 1183–1184

    PubMed  CAS  Google Scholar 

  • Bateman DN, Rawlins MD, Simpson JM (1985) Extrapyramidal reactions with metoclopramide. Br M J 291: 930–932

    CAS  Google Scholar 

  • Brod TM (1989) Fluoxetine and extrapyramidal side effects. Am J Psychiat 146: 1353

    Google Scholar 

  • Brucke T, Wober C, Podreka I et al. (1995) D2 receptor blockade by flunarizine and cinnarizine explain extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab 15: 513–518

    PubMed  CAS  Google Scholar 

  • Ceravolo R, Nuit A, Piccinni A, Dell’Agnello G et al. (2000) Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology 55: 1216–1218

    PubMed  CAS  Google Scholar 

  • Chutorian AM, Bojko A, Heier L, Frucht S, Nygaard T, Edelberg D (2003) Toxic pediatric parkinsonism: report of a child with metabolic studies and repsonse to treatment. J Child Neurol 18: 812–815

    PubMed  Google Scholar 

  • Dell’Agnello G, Ceravolo R, Nuti A et al. (2001) SSRIs do not worsen Parkinson’s disease: evidence from from an open-label, prospective study. Clin Neuropharmacol 24: 221–227

    PubMed  CAS  Google Scholar 

  • Devinsky O, Lemann W, Evans AC, Moeller JR, Rottenberg DA (1987) Akinetic mutism in a bone marrow transplant recipient following totalbody irradiation and amphotericin B chemoprophylaxis: a positron emission tomographic and neuropathologic study. Arch Neurol 44: 414–417

    PubMed  CAS  Google Scholar 

  • DiRocco A, Brannan T, Prikhojan A, Yahr MD (1998) Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm 105: 247–251

    CAS  Google Scholar 

  • Fallgatter AJ, Strik WK (1997) Reversible neuropsychiatrische Nebenwirkungen von Lithium bei normalen Serumspiegeln. Nervenarzt 68: 586–590

    Article  PubMed  CAS  Google Scholar 

  • Fernandez HH, Trieschmann ME, Friedmann JH (2003) Treatment of psychosis in Parkinson’s disease: safety considerations. Drug Saf 26: 643–659

    PubMed  CAS  Google Scholar 

  • Fisher JF, Dewald J (1983) Parkinsonism associated with intraventricular amphotericin B. J Antimicrob Chemother 12: 97–99

    PubMed  CAS  Google Scholar 

  • Fleming DR, Mangino PB (1997) Parkinsonian syndrome in a dialysis-supported patient receiving high-dose chemotherapy for multiple myloma. South Med J 90: 364–365

    PubMed  CAS  Google Scholar 

  • Gajkowski K, Werkowicz-Pelczyk D, Masiak I, Rysz A (1987) Neurologic symptoms in lithium poisoning. Neurol Neurochir Pol 21: 412–414

    PubMed  CAS  Google Scholar 

  • Ganzini L, Casey DE, Hoffman WF, McCall AL (1993) The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 153: 1469–1475

    Article  PubMed  CAS  Google Scholar 

  • Garcia Ruiz PJ, Garcia de Yebenes J et al. (1992) Parkinsonism associated with calcium-channel blockers: a propective follow-up study. Clin Neuropharmacol 15: 19–26

    PubMed  CAS  Google Scholar 

  • Gerber PE, Lynd LD (1998) Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 32: 692–698

    PubMed  CAS  Google Scholar 

  • Ghardirian AM, Annable L, Belanger MC, Chouinard G (1996) A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affectvie disordered patients. J Clin Psychiat 57: 22–28

    Google Scholar 

  • Hardie RJ, Lees AJ (1988) Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosur Ps 51: 850–854

    CAS  Google Scholar 

  • Hassin-Baer S, Sirota P, Korczyn AD (2001) Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 108: 1299–1308

    Article  PubMed  CAS  Google Scholar 

  • Hoffman WF, Labs SM, Casey DE (1987) Neuroleptic-induced parkinsonism in older schizophrenics. Biol Psychiatry 22: 427–439

    Article  PubMed  CAS  Google Scholar 

  • Holroyd S, Smith D (1995) Disabling parkinsonism due to lithium: a case report. J Geriatr Psychiatry Neurol 8: 118–119

    PubMed  CAS  Google Scholar 

  • Indo T, Ando K (1982) Metoclopramide-induced parkinsonism. Arch Neurol 39: 494–496

    PubMed  CAS  Google Scholar 

  • Katz IR, Jeste DV, Mintzer JE et al. (1999) Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiat 60: 107–115

    CAS  Google Scholar 

  • Korczyn AD, Goldgerb GJ (1976) Extrapyramidal effects of neuroleptics. J Neurol Neurosur Ps 39: 866–869

    CAS  Google Scholar 

  • Lecamwasam D, Synek B, Moyles K, Ghose K (1994) Chronic lithium neurotoxicity presenting as Parkinson’s disease. Int Clin Psychopharmacol 9: 127–129

    PubMed  CAS  Google Scholar 

  • Leo RJ (1996) Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Pychiat 57: 449–454

    CAS  Google Scholar 

  • Linn M, Brodt E, Gutschow K, Kolben M (1998) Progression of Parkinson’s disease with impairment of vision under carboplatin/cyclophosphamide therapy for ovarian cancer. Cancer Chemother Pharmacol 41: 427–428

    Article  PubMed  CAS  Google Scholar 

  • Llau ME, Nguyen L, Senard JM, Rascol O, Montastruc JL (1994) Drug-induced parkinsonian syndromes: a 10-year experince at a regional center of pharmaco-vigilance. Rev Neurol 150: 757–762

    PubMed  CAS  Google Scholar 

  • Luque FA, Selhorst JB, Petruska P (1987) Parkinsonism induced by high-dose cytosine arabinoside. Mov Disord 2: 219–222

    Article  PubMed  CAS  Google Scholar 

  • Mangone CA, Herskovits E (1989) Extrapyramidal and depressive side reactions with flunarizine and cinnarizine. J Neurol Neurosur Ps 52: 288–289

    CAS  Google Scholar 

  • Manley TJ, Chusid MJ, Rand SD, Wells D, Margolis DA (1998) Reversible parkinsonism in a child after bone marrow transplantation and lipid-based amphotericin B therapy. Pediatr Infect Dis J 17: 433–434

    PubMed  CAS  Google Scholar 

  • McCreadie RG, Robertson LJ, Wiles DH (1992) The Nithsdale schizophrenia surveys. IX: akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels. Br J Psychiat 161: 739–799

    Google Scholar 

  • Micheli FE, Fernandez Pardal MM, Giannaula R et al. (1989) Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord 4: 139–146

    Article  PubMed  CAS  Google Scholar 

  • Miller LG, Jankovic J (1989) Metoclopramide-induced movement disorders. Arch Intern Med 149: 2486–2492

    PubMed  CAS  Google Scholar 

  • Morgante L, Rocca WA, DiRosa AE et al. (1992) Prevalence of Parkinson’s disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. Neurology 42: 1901–1907

    PubMed  CAS  Google Scholar 

  • Mott SH, Packer RJ, Vezina LG et al. (1995) Enephalopathy with parkinsonian features in children following bone marrow transplantations and high-dose amphotericin B. Ann Neurol 37: 810–814

    Article  PubMed  CAS  Google Scholar 

  • Negrotti A, Calzetti S (1997) A long-term follow-up study of cinnarizine-and flunarizine-induced parkinsonism. Mov Disord 12: 107–110

    Article  PubMed  CAS  Google Scholar 

  • Onofrj M, Thomas A, Paci C (1998) Reversible parkinsonism induced by prolonged treatment with valproate. J Neurol 245: 794–796

    Article  PubMed  CAS  Google Scholar 

  • Pina Latorre MA, Modegro PJ, Rodilla F, Catalan C, Calvo M (2001) Parkinsonism and Parkinson’s disease associated with long-term administration of sertraline. J Clin Pharm Ther 26: 111–112

    Article  PubMed  CAS  Google Scholar 

  • Pranzatelli MR, Mott SH, Pavlakis SG, Conry JA, Tate ED (1994) Clinical spectrum of secondary parkinsonism in childhood: a reversible disorder. Pediatr Neurol 10: 131–140

    Article  PubMed  CAS  Google Scholar 

  • Rajput AH (1984) Drug-induced parkinsonism in the elderly. Geriatr Med Today 3: 99–107

    Google Scholar 

  • Sasso E, Delsoldato S, Negrotti A, Mancia D (1994) Reversible valpraote-induced extrapyramidal disorders. Epilepsia 35: 391–393

    Article  PubMed  CAS  Google Scholar 

  • Schonheyder H, Thestrup-Pedersen K, Esmann V, Stenderup A (1980) Cryptococcal meningitis: complications due to intrathecal treatment. Scand J Infect Dis 12: 155–157

    PubMed  CAS  Google Scholar 

  • Sethi KD, Patel B, Meador KJ (1989) Metoclopramide-induced parkinsonism. South Med J 82: 1581–1582

    PubMed  CAS  Google Scholar 

  • Stadtland C, Erfurth A, Arolt V (2000) De novo onset of Parkinson’s disease after antidepressant treatment with citalopram. Pharmacopsychiatry 33: 194–195

    Article  PubMed  CAS  Google Scholar 

  • Steur EN (1993) Increase of Parkinson disability after fluoxetine medication. Neurology 43: 211–213

    PubMed  CAS  Google Scholar 

  • Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G (2000) Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord 15: 986–989

    Article  PubMed  CAS  Google Scholar 

  • Tollefson GD, Beasley CM, Tamura RN et al. (1997) Blind, controlled, long-term stduy of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiat 154: 1248–1254

    PubMed  CAS  Google Scholar 

  • Tolosa E, Coelho M, Gallardo M (2003) DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 18(suppl 7): 28–33

    Google Scholar 

  • Trenkwalder C, Schwarz J, Gebhard J, Ruland D, Trenkwalder P, Hense H-W, Oertel WH (1995) Stamberg trial on epidemiology of parkinsonism and hypertension in the elderly. Arch Neurol 52: 1017–1022

    PubMed  CAS  Google Scholar 

  • Wasserstein PH, Honig LS (1996) Parkinsonism during cyclosporine treatment. Bone Marrow Transplant 18: 649–650

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologische Klinik Helios-Kliniken Schwerin, Wismarsche Str. 393-397, 19049, Schwerin

    Prof. Dr. med. F. Block

Authors
  1. Prof. Dr. med. F. Block
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurologische Klinik, Helios-Kliniken Schwerin, Wismarsche Straße 392-397, 19049, Schwerin

    Frank Block

  2. Gangelter Einrichtungen Krankenhaus Maria Hilf, Fachkrankenhaus für Psychiatrie und Psychotherapie, Brunchstraße 6, 52538, Gangelt

    Christian Prüter

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Block, F. (2006). Parkinson-Syndrom. In: Block, F., Prüter, C. (eds) Medikamentös induzierte neurologische und psychiatrische Störungen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-28604-7_11

Download citation

  • DOI: https://doi.org/10.1007/3-540-28604-7_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28590-8

  • Online ISBN: 978-3-540-28604-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation